FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC

The FDA has granted Fast Track designation to BH-30643, a drug candidate targeting EGFR C797S mutation-positive non-small cell lung cancer (NSCLC), expediting its development and review process in the United States.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.